Skip to main content

Intraocular Melanoma Clinical Trials

Review the intraocular melanoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 33

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Status: Active
Location: 20 locations
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Status: Active
Location: 17 locations
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Status: Active
Location: 11 locations
Immunotherapy (Tebentafusp) and Radiation Therapy (Yttrium-90 Radioembolization) for the Treatment of Uveal Melanoma Metastatic to the Liver
Status: Active
Location: 8 locations
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Location: 8 locations
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Status: Active
Location: 7 locations
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Status: Active
Location: 7 locations
Cemiplimab in Combination with Ziv-Aflibercept for the Treatment of Metastatic Melanoma
Status: Active
Location: 3 locations
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Status: Active
Location: 6 locations
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Status: Active
Location: 2 locations
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Status: Active
Location: 2 locations
Quisinostat for Preventing Metastasis after Treatment of High-Risk Uveal Melanoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Olaparib in Combination with Pembrolizumab for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Binimetinib plus Belinostat for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Intravenous and Intrathecal Nivolumab or Nivolumab/Relatlimab in Treating Patients with Leptomeningeal Disease
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PRAME-TCR-NK Cells for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Recurrent and/or Refractory Melanoma, PRAMETIME-Mel Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
Status: Active
Location: See ClinicalTrials.gov
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Status: Active
Location: See ClinicalTrials.gov
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Status: Active
Location: 2 locations
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Status: Active
Location: See ClinicalTrials.gov
Tebentafusp-tebn in Combination with Liver-Directed Therapies (TACE and IE) for the Treatment of Metastatic Uveal Melanoma
Status: Approved
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania